Search Result

Results for "

ovarian tumors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (1) ADC Cytotoxin (7) Akt (2) Aldehyde Dehydrogenase (ALDH) (1) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (6) Aurora Kinase (1) Autophagy (2) Bacterial (1) Bcr-Abl (1) Biochemical Assay Reagents (1) Complement System (1) DNA Alkylator/Crosslinker (1) Drug Metabolite (1) Drug-Linker Conjugates for ADC (3) E3 Ligase Ligand-Linker Conjugates (1) EGFR (1) ERK (1) FAK (1) Ferroptosis (2) FLT3 (1) GABA Receptor (1) Glucosylceramide Synthase (GCS) (1) Glutaminase (2) Indoleamine 2,3-Dioxygenase (IDO) (2) Macrophage migration inhibitory factor (MIF) (1) Microtubule/Tubulin (1) NAMPT (1) Necroptosis (1) Notch (1) Oct3/4 (1) PARP (3) Phosphatase (1) Polo-like Kinase (PLK) (1) Proteasome (1) Reactive Oxygen Species (2) Reverse Transcriptase (1) STAT (1) TNF Receptor (1) Topoisomerase (7)
By Research Areas:	Cancer (50) Infection (1) Inflammation/Immunology (4) Metabolic Disease (3)

By Targets:

ADC Antibody (1)

ADC Cytotoxin (7)

Akt (2)

Aldehyde Dehydrogenase (ALDH) (1)

Antibody-Drug Conjugates (ADCs) (1)

Apoptosis (6)

Aurora Kinase (1)

Autophagy (2)

Bacterial (1)

Bcr-Abl (1)

Biochemical Assay Reagents (1)

Complement System (1)

DNA Alkylator/Crosslinker (1)

Drug Metabolite (1)

Drug-Linker Conjugates for ADC (3)

E3 Ligase Ligand-Linker Conjugates (1)

EGFR (1)

ERK (1)

FAK (1)

Ferroptosis (2)

FLT3 (1)

GABA Receptor (1)

Glucosylceramide Synthase (GCS) (1)

Glutaminase (2)

Indoleamine 2,3-Dioxygenase (IDO) (2)

Macrophage migration inhibitory factor (MIF) (1)

Microtubule/Tubulin (1)

NAMPT (1)

Necroptosis (1)

Notch (1)

Oct3/4 (1)

PARP (3)

Phosphatase (1)

Polo-like Kinase (PLK) (1)

Proteasome (1)

Reactive Oxygen Species (2)

Reverse Transcriptase (1)

STAT (1)

TNF Receptor (1)

Topoisomerase (7)

By Research Areas:

Cancer (50)

Infection (1)

Inflammation/Immunology (4)

Metabolic Disease (3)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-139453

LP-184	Others	Cancer
LP-184 (compound 6), an acylfulvene analog, inhibits tumor growth. LP-184 has potent anti-cancer activity in the ovarian, colon, prostate and pancreatic cell lines. (patent WO2007019308A2).

HY-N0462

Corilagin 2 Publications Verification	Reverse Transcriptase Bacterial Apoptosis Autophagy	Infection Inflammation/Immunology Cancer
Corilagin, a gallotannin, has anti-tumor, anti-inflammatory and hepatoprotective activities. Corilagin inhibits activity of reverse transcriptase of RNA tumor viruses. Corilagin also inhibits the growth of Staphylococcus aureus with a MIC of 25 μg/mL. Corilagin shows anti-tumor activity on hepatocellular carcinoma and ovarian cancer model. Corilagin shows low toxicity to normal cells and tissues .

HY-P99386

Vesencumab MNRP-1685A	Complement System	Cancer
Vesencumab (MNRP-1685A) is IG1 antibody against neuropilin-1 (NRP-1). Vesencumab binds to NRP-1 and prevents the subsequent coupling of NRP-1 to VEGFR-2. Vesencumab has anti-angiogenic and anti-neoplastic activities. Vesencumab can be used in the research of metastatic solid tumors, including ovarian cancer .

HY-133800

Volvaltrate B	Biochemical Assay Reagents	Cancer
Volvaltrate B is an anticancer agent, iridoid, can be obtained from the root of valerian (Valeriana officinalis). Volvaltrate B is effective against ovarian tumors in female mice. Volvaltrate B has the potential to study cancer .

HY-122912

ALDH1A inhibitor 673A ALDH1Ai 673A	Aldehyde Dehydrogenase (ALDH) Necroptosis	Cancer
ALDH1A inhibitor 673A is an ALDH1A inhibitor. ALDH1A inhibitor 673A inhibits all three ALDH1A family members (IC₅₀: 246 nM, 230 nM, 348 nM for ALDH1A1, ALDH1A2, ALDH1A3 respectively. ALDH1A inhibitor 673A induces necroptotic cell death preferentially in CD133+ ovarian CSCs. ALDH1A inhibitor 673A also inhibits chemotherapy-resistant tumor growth .

HY-143407

FAK-IN-3	FAK	Cancer
FAK-IN-3 (Compound 36) is a potent inhibitor of focal adhesion kinase (FAK). FAK-IN-3 not only decreases migration and invasion of PA-1 cells, but also reduces expression of MMP-2 and MMP-9. FAK-IN-3 inhibits tumor growth and metastasis, and no obvious adverse effects. FAK-IN-3 has the potential for the research of ovarian cancer .

HY-16503

Treosulfan 2 Publications Verification NSC 39069; Treosulphan	DNA Alkylator/Crosslinker	Cancer
Treosulfan (NSC 39069) is a bifunctional alkylating agent with activity in ovarian cancer and other solid tumor types.

HY-107008

SW 71425

Others Cancer

SW 71425 inhibits cell growth against breast, colon, non-small cell lung, and ovarian tumors. .

SW 71425	Others	Cancer
SW 71425 inhibits cell growth against breast, colon, non-small cell lung, and ovarian tumors. .

HY-14375

CB 300919	NAMPT	Cancer
CB 300919 is a quinazoline-based antitumour agent with high activity in the CH1 human ovarian tumour xenograft. CB 300919 has a continuous exposure (96 h) growth inhibition IC₅₀ value of 2 nM in human CH1 ovarian tumor xenograft .

HY-P99547

Trastuzumab duocarmazine (vic)-Trastuzumab duocarmazine	Antibody-Drug Conjugates (ADCs)	Cancer
Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting ADC that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas .

HY-153909

SMP-33693	Drug-Linker Conjugates for ADC	Cancer
SMP-33693 is a Drug-Linker Conjugate for ADC with a low payload shedding rate and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer .

HY-153908

SMP-93566	Drug-Linker Conjugates for ADC	Cancer
SMP-93566 is a kind of antibody-drug conjugates (ADCs) with a low payload shedding rate and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer .

HY-128595

MT-4	Others	Cancer
MT-4 blocks the TG2/FN complex at the interface between cancer cells and the tumor niche. MT-4 inhibits the adhesion of ovarian cancer (OC) cells to the peritoneum .

HY-153907

SMP-88480	Drug-Linker Conjugates for ADC	Cancer
SMP-88480 is an Antibody-Drug Conjugates (ADCs). SMP-88480 is stable in mouse, monkey and human plasma and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer .

HY-127079

Epothilone F	Microtubule/Tubulin	Cancer
Epothilone F is a Microtubule/Tubulin-stabilizing agent with anti-tumor activity. Epothilone F inhibits the proliferation of breast cancer cells, non-small cell lung cancer cells, drug-resistant ovarian cancer cells .

HY-116392B

DL-threo-PDMP hydrochloride	Glucosylceramide Synthase (GCS)	Cancer
DL-threo-PDMP hydrochloride is the hydrochloride form of DL-threo-PDMP that is a competitive glucosylceramide synthase (GCS) inhibitor. DL-threo-PDMP resensitizes refractory testicular germ cell tumors and epithelial ovarian cancer orthoxenografts to cisplatin in mice .

HY-W021377C

Exatecan Intermediate 4 dihydrochloride	ADC Cytotoxin Topoisomerase	Cancer
Exatecan Intermediate 4 dihydrochloride is an intermediate of Exatecan (DX-8951, HY-13631). Exatecan is an anticancer agent belonging to the class of camptothecin analogs. Exatecan interferes with the proliferation and division of tumor cells by interacting with DNA, thereby inhibiting tumor growth. Exatecan is primarily used for research of a variety of cancers including ovarian, lung and breast cancers .

HY-P99506

Tamrintamab SC-003 mAb; SC-Mab003; SC34.28ss1	ADC Antibody	Cancer
Tamrintamab (SC-003 mAb, SC-Mab003, SC34.28ss1) is an ADC Antibody targeting to dipeptidase 3 (DPEP3 or MBD3). DPEP3 is a glycosyl phosphatidylinositol anchored metallopeptidase that is overexpressed in ovarian tumors. Tamrintamab can specifically bind DPEP3-expressing cells to produce cytotoxicity. Tamrintamab can be used in ovarian cancer research .

HY-W021377

Exatecan Intermediate 2	ADC Cytotoxin Topoisomerase	Cancer
Exatecan Intermediate 2 (compound B) is an intermediate of Exatecan (DX-8951, HY-13631). Exatecan is an anticancer agent belonging to the class of camptothecin analogs. Exatecan interferes with the proliferation and division of tumor cells by interacting with DNA, thereby inhibiting tumor growth. Exatecan is primarily used for research of a variety of cancers including ovarian, lung and breast cancers .

HY-42487

Exatecan Intermediate 1	ADC Cytotoxin Topoisomerase	Cancer
Exatecan Intermediate 1 (compound 6) is an intermediate of Exatecan (DX-8951, HY-13631). Exatecan is an anticancer agent belonging to the class of camptothecin analogs. Exatecan interferes with the proliferation and division of tumor cells by interacting with DNA, thereby inhibiting tumor growth. Exatecan is primarily used for research of a variety of cancers including ovarian, lung and breast cancers .

HY-W021377A

Exatecan Intermediate 2 hydrochloride	ADC Cytotoxin Topoisomerase	Cancer
Exatecan Intermediate 2 hydrochloride (compound B) is an intermediate of Exatecan (DX-8951, HY-13631). Exatecan is an anticancer agent belonging to the class of camptothecin analogs. Exatecan interferes with the proliferation and division of tumor cells by interacting with DNA, thereby inhibiting tumor growth. Exatecan is primarily used for research of a variety of cancers including ovarian, lung and breast cancers .

HY-W021377B

Exatecan Intermediate 4	ADC Cytotoxin Topoisomerase	Cancer
Exatecan Intermediate 4 (compound B) is an intermediate of Exatecan (DX-8951, HY-13631). Exatecan is an anticancer agent belonging to the class of camptothecin analogs. Exatecan interferes with the proliferation and division of tumor cells by interacting with DNA, thereby inhibiting tumor growth. Exatecan is primarily used for research of a variety of cancers including ovarian, lung and breast cancers .

HY-42487A

(rac)-Exatecan Intermediate 1	ADC Cytotoxin Topoisomerase	Cancer
(rac)-Exatecan Intermediate 1 is an isomer of Exatecan Intermediate 1 (HY-42487). Exatecan Intermediate 1 (compound 6) is an intermediate of Exatecan (HY-13631), a camptothecin-based anticancer agent. Exatecan inhibits tumor growth by interfering with the proliferation and division of tumor cells by interacting with DNA. Exatecan is primarily used in research into a variety of cancers including ovarian, lung and breast cancer .

HY-42487B

(R)-Exatecan Intermediate 1	ADC Cytotoxin Topoisomerase	Cancer
(R)-Exatecan Intermediate 1 is an isomer of Exatecan Intermediate 1 (HY-42487). Exatecan Intermediate 1 (compound 6) is an intermediate of Exatecan (HY-13631), a camptothecin-based anticancer agent. Exatecan inhibits tumor growth by interfering with the proliferation and division of tumor cells by interacting with DNA. Exatecan is primarily used in research into a variety of cancers including ovarian, lung and breast cancer .

HY-136563

RA375	Proteasome Apoptosis Reactive Oxygen Species	Cancer
RA375 is a RPN13 (26S proteasome regulatory subunit) inhibitor. RA375 activates UPR signaling, ROS production and apoptosis. RA375 exhibits ten-fold greater activity against cancer lines than RA190, reflecting its nitro ring substituents and the addition of a chloroacetamide warhead .

HY-13072

Cenisertib 1 Publications Verification AS-703569; R-763	Aurora Kinase Bcr-Abl Akt STAT FLT3	Cancer
Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia .

HY-B0380A

Trimebutine maleate	Oct3/4 ERK Akt Apoptosis	Metabolic Disease Cancer
Trimebutine maleate is an orally anti-tumor agent. Trimebutine maleate selectively suppresses stemness and proliferation of ovarian cancer stem cells (CSCs). Trimebutine maleate reduces the colonic muscle hypercontractility, modulates gastrointestinal motility, induces apoptosis and can be used for the research of glioma/glioblastoma and irritable bowel syndrome .

HY-106376A

L-Buthionine-(S,R)-sulfoximine Maximum Cited Publications 6 Publications Verification L-Buthionine sulfoximine; L-BSO	Ferroptosis	Cancer
L-Buthionine-(S,R)-sulfoximine is a cell-permeable, potent, fast acting and irreversible inhibitor of g-glutamylcysteine synthetase and depletes cellular glutathione levels. The IC₅₀ value of L-Buthionine-(S,R)-sulfoximine on melanoma, breast and ovarian tumor specimens are 1.9 μM, 8.6 μM, and 29 μM, respectively.

HY-122650

PHY34	Autophagy	Cancer
PHY34 is an inhibitor that inhibits ATP6V0A2 and CAS thereby inhibiting autophagy, and has a nanomolar effect. PHY34 inhibits cancer cell growth by inducing apoptosis and inhibits tumor growth in xenograft models. PHY34 can be used for research on high grade serous ovarian cancer .

HY-100433

PACMA 31
PACMA 31 is an irreversible, orally active protein disulfide isomerase (PDI) inhibitor with an IC₅₀ of 10 μM. PACMA 31 forms a covalent bond with the active site cysteines of PDI. PACMA 31 shows tumor targeting ability and significantly suppresses ovarian tumor growth without causing toxicity to normal tissues . PACMA 31 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-155458

HYDAMTIQ	PARP	Inflammation/Immunology Cancer
HYDAMTIQ is a PARP-1/2 inhibitor (IC₅₀: 29-38 nM) with anticancer, anti-inflammatory, and ischemic protective effects. HYDAMTIQ inhibits pulmonary PARP activity, is effective against allergen-induced cough and dyspnea, and inhibits bronchial hyperresponsiveness to methacholine. HYDAMTIQ has broad-spectrum tumor suppressor effects, including ovarian and breast cancers, prostate and pancreatic tumors, and glioblastoma multiforme. HYDAMTIQ has demonstrated in vivo efficacy in animal models of cerebral ischemia, asthma, cancer, and more .

HY-147298

Plogosertib CYC140	Polo-like Kinase (PLK)	Cancer
Plogosertib (CYC140) is a selective, potent, and orally active ATP-competitive PLK1 inhibitor (IC₅₀: 3 nM). Plogosertib is an anti-cancer agent with anti-proliferative activity. Plogosertib can be used in the research of several tumors, including esophageal, gastric, leukemia, non–small cell lung cancer, ovarian, and squamous cell cancers .

HY-106376C

L-Buthionine-(S,R)-sulfoximine hydrochloride Maximum Cited Publications 6 Publications Verification L-Buthionine sulfoximine hydrochloride; L-BSO hydrochloride	Ferroptosis	Metabolic Disease Cancer
L-Buthionine-(S,R)-sulfoximine hydrochloride is a cell-permeable, potent, fast acting, orally active and irreversible inhibitor of g-glutamylcysteine synthetase and depletes cellular glutathione levels. The IC₅₀ value of L-Buthionine-(S,R)-sulfoximine on melanoma, breast and ovarian tumor specimens are 1.9 μM, 8.6 μM, and 29 μM, respectively .

HY-103671A

IPN60090 dihydrochloride	Glutaminase	Inflammation/Immunology Cancer
IPN-60090 dihydrochloride is an orally active and highly selective inhibitor of glutaminase 1 (GLS1; IC₅₀=31 nM), with no activity observed against GLS-2. IPN-60090 dihydrochloride exhibits excellent physicochemical and pharmacokinetic properties in vivo. IPN-60090 dihydrochloride can be used for solid tumors research, such as lung and ovarian cancers .

HY-103671

IPN60090	Glutaminase	Inflammation/Immunology Cancer
IPN-60090 is an orally active and highly selective inhibitor of glutaminase 1 (GLS1; IC₅₀=31 nM), with no activity observed against GLS-2. IPN-60090 exhibits excellent physicochemical and pharmacokinetic properties in vivo. IPN-60090 can be used for solid tumors research, such as lung and ovarian cancers .

HY-P99925

Enoticumab REGN421	Notch	Metabolic Disease Cancer
Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively .

HY-109583

4-Oxofenretinide 4-Oxo-4-HPR	Apoptosis Reactive Oxygen Species Drug Metabolite	Cancer
4-Oxofenretinide (4-Oxo-4-HPR) is a metabolite of Fenretinide (HY-15373). 4-Oxofenretinide induces cell growth inhibition in ovarian, breast, and neuroblastoma tumor cell lines. 4-Oxofenretinide causes a marked accumulation of cells in G2-M. 4-Oxofenretinide induces cancer cell apoptosis through caspase-9 .

HY-135457

JMS-053	Phosphatase	Cancer
JMS-053 is a potent, selective and reversible PTP4A inhibitor, with IC₅₀s of 29.1 nM, 48.0 nM, 34.7 nM, 92.6 nM, and 207.6 nM for PTP4A1, PTP4A2, PTP4A3, CDC25B, and DUSP3, respectively. JMS-053 can inhibit cancer cell migration and spheroid growth in vitro, attenuate in vivo ovarian tumor growth .

HY-P99262

Imalumab BAX69; Anti-Human MIF Recombinant Antibody	Macrophage migration inhibitory factor (MIF)	Cancer
Imalumab (BAX69) is a recombinant, human IgG1 monoclonal antibody that targets macrophage inhibitory factor (MIF). Imalumab can be used for the research of ovarian carcinoma, recurrent malignant ascites and cancer .

HY-19671

Apomine SR-45023A; SR 9223i; SK&F-99085	Apoptosis	Cancer
Apomine (SR-45023A) is an antineoplastic agent that inhibits the mevalonate/isoprenoid pathway in cholesterol synthesis. It can accelerate the degradation of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR). Apomine can also inhibit the growth of various types of cancer cells, including lung cancer, colon cancer, breast cancer, and skin cancer. In addition, Apomine is able to induce apoptosis in tumor cell lines derived from leukemia, colon cancer, liver cancer, ovarian cancer, and breast cancer .

HY-144274

IDO1-IN-14	Indoleamine 2,3-Dioxygenase (IDO)	Cancer
IDO1-IN-14 (compound 4a) is a potent IDO1 inhibitor with an IC₅₀ of 396.9 nM. IDO1-IN-14 has cellular IDO1 inhibition (HeLa EC₅₀=3393 nM) .

HY-144273

IDO1-IN-13	Indoleamine 2,3-Dioxygenase (IDO)	Cancer
IDO1-IN-13 (compound 27a) is a potent IDO1 inhibitor with an IC₅₀ of 61.6 nM. IDO1-IN-13 has cellular IDO1 inhibition (HeLa EC₅₀= 30 nM). IDO1-IN-13 decreases 51% of the kyn/trp ratio in SK-OV-3 xenograft tumor tissues .

HY-N2080

Songorine	GABA Receptor	Cancer
Songorine is a diterpenoid alkaloid isolated from the genus Aconitum. Songorine is a GABAA receptor antagonist in rat brain and has anti cancer, antiarrhythmic and anti-inflammatory activities. Songorine has the potential for the treatment of Epithelial ovarian cancer (EOC) .

HY-136174

RBN-2397 Maximum Cited Publications 6 Publications Verification	PARP	Cancer
RBN-2397 is a potent, accross species and orally active NAD ⁺ competitive inhibitor of PARP7 (IC₅₀<3 nM). RBN-2397 selectively binds to PARP7 (K_d=0.001 μM) and restores IFN signaling. RBN-2397 has the potential for the study of advanced or metastatic solid tumors .

HY-N3446

IVHD-valtrate	Apoptosis	Cancer
IVHD-valtrate, an active Valeriana jatamansi derivative, is against human ovarian cancer cells in vitro and in vivo. IVHD-valtrate induces cancer cells apoptosis and arrests the ovarian cancer cells in the G2/M phase. IVHD-valtrate has the potential to be a novel chemotherapeutic agent for the human ovarian cancer research .

HY-75706

N-Descyclopropanecarbaldehyde Olaparib	E3 Ligase Ligand-Linker Conjugates PARP	Cancer
N-Descyclopropanecarbaldehyde Olaparib is an analogue of Olaparib containing DOTA moiety. N-Descyclopropanecarbaldehyde Olaparib is a CRBN-based ligand for synthesizing novel dual EGFR and PARP PROTAC, DP-C-4 . N-Descyclopropanecarbaldehyde Olaparib can be radiolabeled F-18 or fluorophore for positron emission tomography (PET) or optical imaging in several types of tumor .

HY-P99605

Cinrebafusp alfa PRS 343	EGFR TNF Receptor	Cancer
Cinrebafusp alfa (PRS 343) is a high affinity CD137/HER2 bispecfic anticalin-based drug. Cinrebafusp alfa binds to recombinant human HER2 (K_d=0.3 nM) and human monomeric CD137 (4-1BB; K_d=5 nM). Cinrebafusp alfa facilitates T-cell costimulation by tumor-localized, HER2-dependent 4-1BB clustering and activation, further enhancing T-cell receptor-mediated activity and leading to tumor destruction. Cinrebafusp alfa has the potential for HER2+ solid tumors research .

Cat. No.	Product Name

HY-L173

Anti-Ovarian Cancer Compound Library

1883 Compounds compounds

Ovarian cancer is the most common cause of death in female genital malignancies, with the highest mortality rate in female genital malignancies. It is characterized by difficulty in detection in the early stage of the disease, high recurrence rate and poor prognosis. In fact, ovarian cancer includes many pathologic types. It is usually divided into epithelial ovarian cancer, malignant germ cell tumors and sex cord stromal tumors, of which epithelial ovarian cancer is the most dominant form. Clinical treatment of ovarian cancer prioritizes surgery combined with paclitaxel chemotherapy. However, due to the spread and drug resistance of tumor cells, the recurrence of ovarian cancer is high. In this case, combined with traditional methods, the development of new therapeutic agents can help to improve the treatment effect of ovarian cancer.

MCE designs a unique collection of 1883 compounds with definite or potential anti-ovarian cancer activity, which mainly targeting the main targets of ovarian cancer such as PARP, ATM/ATR, VEGFR and HIF/HIF Prolyl-Hydroxylase, etc. It is an essential tool for development and research of anti-ovarian compounds.

Cat. No.	Product Name	Target	Research Area

HY-P5098

E(c(RGDfK))2	Peptides	Cancer
E(c(RGDfK)) is an αvβ3 integrin-specific binding moiety with tumor targeting properties. Increased uptake of E(c(RGDfK)) in human ovarian cancer OVCAR-3 xenograft tumors may be useful in cancer research .

Cat. No.	Product Name	Target	Research Area

HY-P99386

Vesencumab MNRP-1685A	Complement System	Cancer
Vesencumab (MNRP-1685A) is IG1 antibody against neuropilin-1 (NRP-1). Vesencumab binds to NRP-1 and prevents the subsequent coupling of NRP-1 to VEGFR-2. Vesencumab has anti-angiogenic and anti-neoplastic activities. Vesencumab can be used in the research of metastatic solid tumors, including ovarian cancer .

HY-P99547

Trastuzumab duocarmazine (vic)-Trastuzumab duocarmazine	Antibody-Drug Conjugates (ADCs)	Cancer
Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting ADC that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas .

HY-P99413

IMAB027 ASP1650	Inhibitory Antibodies	Cancer
IMAB027 (ASP1650) is a specific anti-CLDN6 mAb, while CLDN6 (Claudin 6) is a tight junction membrane protein, aberrantly expressed in various human cancer types, ovarian cancers particularly. IMAB 027 shows anti-tumor activity, and induces apoptosis in CLDN6 ⁺ ovarian and testicular cancer cell lines .

HY-P99179

CTX-2026	Inhibitory Antibodies	Cancer
CTX-2026 is a fully human antibody that binds to CD277. CTX-2026 shows an anti-tumor effect on ovarian tumor models. CTX-2026 can be used for the research of cancer .